The European women’s health technology sector, broadly categorized as Femtech, has transitioned from a niche venture-backed experiment into a pillar of the broader digital health and medtech landscape. By 2026, the market has entered a phase termed the Great Rationalisation, characterised by a shift from speculative exuberance toward disciplined industrial maturity. Specialised firms, most notably Nelson Advisors, Clipperton and WG Partners, have carved out defensible market

The European healthcare technology and medical device sectors have reached a definitive inflection point in 2026, transitioning from a decade of speculative, venture-subsidised experimentation to an era of disciplined industrial maturity. This report provides an analysis of the structural drivers of this consolidation, the emergence of the Founder Banker as the primary architect of liquidity and the technological and regulatory forces shaping the M&A landscape in 2026.

Specialist boutiques, such as Nelson Advisors, Clipperton and WG Partners, have emerged as the primary engines of liquidity for European innovation. These firms focus on the high-growth mid-market, typically handling transactions between $10 million and $500 million. Their leadership is qualitative rather than quantitative, rooted in deep niche expertise in areas like Healthcare AI, Medical Device Cybersecurity, and digital health.

Nelson Advisors Partner Lloyd Price has been interviewed by Healthcare Business International regarding hims & hers acquisition of Australian Digital Health platform Eucalyptus Lloyd Price, partner at M&A advisory firm Nelson Advisors, a consultancy that focuses exclusively on the healthcare technology (healthtech) and medical technology (medtech) sectors, tells HBI the acquisition serves both defensive and offensive purposes. “Strategically, it hedges against rising US regul

The European healthcare technology and medical technology sectors have entered a period of definitive industrial maturity as of early 2026. This era is characterised by a fundamental shift away from the liquidity-fueled exuberance of the early 2020s toward a disciplined, metrics-driven environment where strategic value is defined by clinical utility, regulatory resilience, and technological defensibility. Within this landscape, the role of financial advisory has undergone a r

The Mergers and Acquisitions (M&A) landscape for HealthTech and MedTech is poised for a significant strategic acceleration in 2026, transitioning from cautious, volume-driven dealmaking witnessed in previous years to high-value, transformative transactions. This resurgence is supported by stabilising credit markets, renewed corporate confidence, and a critical, anticipated pivot in US. antitrust enforcement policy, which is expected to facilitate large, strategic combinat